The Medical Letter on Drugs and Therapeutics
Trumenba: A Serogroup B Meningococcal Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.

SEROGROUP B MENINGOCOCCAL VACCINES — Until recently, no serogroup B meningococcal vaccine was available in the US because the polysaccharide capsule of the B serogroup is only weakly immunogenic. A different meningococcal B vaccine (4CMenB; Bexsero) has been approved for use in Canada, the European Union, and Australia. In late 2013 and early 2014, the FDA and the CDC permitted the importation and investigational use of Bexsero in two outbreaks of serogroup B meningococcal disease.1

MENINGOCOCCAL DISEASE — Five major serogroups (A, B, C, Y, and W-135) of N. meningitidis cause most invasive meningococcal ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Trumenba: A Serogroup B Meningococcal Vaccine
Article code: 1459d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian